Shared on01 Aug 25Fair value Decreased 14%
NovoCure’s fair value estimate fell as its future P/E multiple contracted notably and its discount rate increased, leading to a lower consensus analyst price target of $27.19. What's in the News NovoCure to present final secondary endpoint results from Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer at ESMO GI Cancers Congress 2025, focusing on quality of life outcomes and time to first opioid use.
Shared on24 Apr 25Fair value Decreased 4.18%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 8.83%
AnalystConsensusTarget has increased revenue growth from 8.5% to 9.5%.
Shared on02 Apr 25Fair value Increased 1.29%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 9.08%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.